Literature DB >> 29122917

Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.

Liga Kuksa1, Linda Barkane1, Norbert Hittel2, Rajesh Gupta3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29122917     DOI： 10.1183/13993003.01105-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

2.  Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Authors:  Zhiyi Lan; Nafees Ahmad; Parvaneh Baghaei; Linda Barkane; Andrea Benedetti; Sarah K Brode; James C M Brust; Jonathon R Campbell; Vicky Wai Lai Chang; Dennis Falzon; Lorenzo Guglielmetti; Petros Isaakidis; Russell R Kempker; Maia Kipiani; Liga Kuksa; Christoph Lange; Rafael Laniado-Laborín; Payam Nahid; Denise Rodrigues; Rupak Singla; Zarir F Udwadia; Dick Menzies
Journal:  Lancet Respir Med       Date:  2020-03-17       Impact factor: 30.700

3.  Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.

Authors:  R R Kempker; L Mikiashvili; Y Zhao; D Benkeser; K Barbakadze; N Bablishvili; Z Avaliani; C A Peloquin; H M Blumberg; M Kipiani
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

Review 4.  New Drugs for the Treatment of Tuberculosis.

Authors:  Elisa H Ignatius; Kelly E Dooley
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 4.967

5.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

Review 6.  New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Authors:  Denise Rossato Silva; Margareth Dalcolmo; Simon Tiberi; Marcos Abdo Arbex; Marcela Munoz-Torrico; Raquel Duarte; Lia D'Ambrosio; Dina Visca; Adrian Rendon; Mina Gaga; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2018-04       Impact factor: 2.624

7.  Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes.

Authors:  Eun Hye Lee; Seung Hyun Yong; Ah Young Leem; Sang Hoon Lee; Song Yee Kim; Kyung Soo Chung; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Joon Chang; Young Ae Kang
Journal:  Open Forum Infect Dis       Date:  2019-04-01       Impact factor: 3.835

Review 8.  Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.

Authors:  Yang Li; Feng Sun; Wenhong Zhang
Journal:  Drug Dev Res       Date:  2018-12-11       Impact factor: 4.360

9.  Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.

Authors:  Alfred A Lardizabal; Anum N Khan; Sapna Bamrah Morris; Neela D Goswami
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-09-07       Impact factor: 17.586

10.  Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.

Authors:  Erika Mohr; Jennifer Hughes; Anja Reuter; Laura Trivino Duran; Gabriella Ferlazzo; Johnny Daniels; Virginia De Azevedo; Yulene Kock; Sarah Jane Steele; Amir Shroufi; Serge Ade; Natavan Alikhanova; Guido Benedetti; Jeffrey Edwards; Helen Cox; Jennifer Furin; Petros Isaakidis
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.